Rhonda Patrick· PhD
And the surprise was, all the people who have Alzheimer's are very poor at eating and getting rid of this amyloid.
Loading…
The headline is broadly defensible, but the qualifications matter. Effect sizes vary by population, the strongest claims rest on shorter trials, and credible voices push back on how it's typically framed.
And the surprise was, all the people who have Alzheimer's are very poor at eating and getting rid of this amyloid.
Every Sunday: the week’s new conflicts and verdict changes — and nothing else.
Native comments, Twitter mentions, and Reddit threads about this claim — surfaced together so the conversation isn't fragmented across platforms.
Bookmarking — the dossier-vs-overview split is the right call. Most of the time I want overview; sometimes I want receipts.
Would love a "what would change this verdict" RSS feed. Sign me up if it exists.
This paper that you are referring to, I do remember reading a paper that you had published a few years ago where you had taken this, essentially, I guess, you can use that as a biomarker if the people with Alzheimer's disease are not clearing amyloid beta plaques via phagocytosis with their monocytes effectively, that's sort of kind of a surrogate marker for what's going on in the brain potentially, right?